Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT04430283
Other study ID # FDY-5301-203
Secondary ID
Status Terminated
Phase Phase 2
First received
Last updated
Start date September 20, 2021
Est. completion date March 4, 2022

Study information

Verified date June 2023
Source Faraday Pharmaceuticals, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics (PK) of FDY-5301 compared to placebo in major trauma ICU patients at risk of intensive care unit acquired weakness (ICUAW)


Description:

The purpose of the trial is to evaluate the efficacy, safety, and PK of FDY-5301 compared to placebo in trauma ICU patients at risk of ICUAW. Muscle wasting occurs rapidly after major trauma and is often associated with multi-organ failure lasting from a few weeks to a long term disability. It is believed that FDY-5301 may help prevent or treat muscle weakness and organ dysfunction in major trauma patients. Approximately 252 subjects will be randomized (1:1:1) to receive up to 7 daily bolus IV doses of FDY-5301 at 1 mg/kg or 2 mg/kg, or volume-matched placebo. To ensure equal representation in each group, the randomization will be stratified by the presence or absence of any pelvic or lower limb fractures. All subjects who satisfy the eligibility criteria will be randomly allocated to one of three treatment groups (FDY-5301 low dose, FDY-5301 high dose, or placebo). All subjects will be followed for 6 months. This study will be conducted globally.


Recruitment information / eligibility

Status Terminated
Enrollment 8
Est. completion date March 4, 2022
Est. primary completion date March 4, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. Age 18-75 years 2. Major trauma defined as: 1. thoracic and/or abdominal and/or pelvic injury 2. necessitating admission to ICU with ventilation anticipated for at least 24 hrs 3. hemorrhagic shock defined as systolic blood pressure (SBP) <90 mmHG requiring blood transfusion or base deficit of at least 6mEq/L pre-hospital arrival or within one hour after hospital arrival 3. IRB/IEC-approved consent obtained within 48 hours of first hospital arrival time (i.e., in case of transfers, use time of arrival to first hospital immediately post injury) Exclusion Criteria: 1. Likely to die within 48 hrs from time of screening 2. Any neurological condition that is perceived at the time of hospital admission as an immediate threat to life or incompatible with good functional recovery and where early limitation or withdrawal of therapy is being considered. For example: a. Computed tomography imaging showing evidence of traumatic brain injury (TBI), combined with best representative Glasgow Coma Score (GCS) Motor Score of =4 at approximately 24 hrs post injury 3. Evidence of nonreversible spinal cord injury 4. Bilateral femoral fractures 5. Women who are pregnant or breastfeeding. Women of reproductive potential must have a negative serum pregnancy test prior to randomization. 6. Known thyroid disease or thyroid disorder, including subjects on thyroid hormone replacement therapy at the time of randomization 7. Known allergy to iodine 8. Chronic renal disease requiring dialysis 9. Body mass index (BMI) >40 kg/m2 or <16 kg/m2 10. Body weight (BW) >140 kg (or >309 lb) 11. History or presence of debilitating neurologic or other neuromuscular disease (e.g., spina bifida, amyotrophic lateral sclerosis, multiple sclerosis) at time of randomization 12. Current metastatic cancer 13. Solid organ transplant recipient 14. Evidence of pre-existing sarcopenia defined as having a pre-trauma Clinical Frailty Score (CFS) of =5 or based on clinical judgement (e.g. frail by appearance, cachexia, etc.) 15. Use of systemic corticosteroids, immunomodulators, or oncologic chemotherapy within 6 months of randomization (inhaled and topical steroids are allowed) 16. Use of investigational drugs or devices within 30 days of randomization 17. Any clinically significant abnormality identified prior to randomization that in the judgment of the Investigator or Sponsor would preclude safe completion of the study, or confound the anticipated benefit of FDY-5301

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
FDY-5301
FDY-5301 is Sodium Iodide administered as an isotonic solution for intravenous injection with a concentration of 7.2 mg/ml.
Other:
Placebo
Placebo is delivered as a single dose, non-reserved liquid parenteral consisting of a formulation matched compendial saline.

Locations

Country Name City State
United States Massachusetts General Hospital, Harvard Medical School Boston Massachusetts
United States The Ohio State University Wexner Medical Center Columbus Ohio
United States University of Florida Health Shands Hospital Gainesville Florida
United States Harborview Seattle Washington
United States Harbor-UCLA Medical Center Torrance California

Sponsors (1)

Lead Sponsor Collaborator
Faraday Pharmaceuticals, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Chelsea Critical Care Physical Assessment Tool Chelsea Critical Care Physical Assessment Tool (CPAx) total score at Day 10, or hospital discharge, whichever occurs first. The Chelsea Critical Care Physical Assessment Tool components will be graded on a 6-point scale from dependent to independent (0 to 5). The individual values will be collated giving a total score out of 50. A higher score indicates a better outcome. Day 10 or hospital discharge, whichever occurs first.
Primary Organ Dysfunction Total Time to Recovery Organ dysfunction total time to recovery (TTR) until Day 28 Day 28 or hospital discharge, whichever occurs first.
Secondary Medical Research Council Sum Score Medical Research Council Sum Score (MRC-SS) at Day 28, or hospital discharge, whichever occurs first. The Medical Research Council Sum Score measures global peripheral muscle strength which ranges from 0 (complete paralysis) to 60 (normal strength). A higher score indicates a better outcome. Day 28, or hospital discharge, whichever occurs first
Secondary Sequential Organ Failure Assessment Score The Sequential Organ Failure Assessment (SOFA) is a scoring system that assesses the performance of several organ systems in the body and assigns a score based on the data obtained in each category, this is scored during the ICU stay. The full-length Sequential Organ Failure Assessment score ranges from 0 to 24. A higher score indicates a worse outcome. ICU hospital stay until Day 28 or ICU discharge if earlier
Secondary Overall Survival at Day 28 Confirmation of survival status will be obtained by speaking directly with subject, via medical records, or public health records. Day 28
See also
  Status Clinical Trial Phase
Completed NCT05527678 - 5 Years Quality of Life and Early Mobilization in ICU
Recruiting NCT05537298 - Muscle Recovery After Critical Illness
Completed NCT05473546 - Diarrhea and Stipsis in Critically Ill Patients (NUTRITI)
Not yet recruiting NCT05326633 - Effect of Protein, Mobility Therapy and Electric Stimulation on Recovery in Older ICU Survivors Early Phase 1
Not yet recruiting NCT06025760 - Evaluation of Diaphragmatic Function and Quadriceps Muscle Thickness in Patients Receiving High Protein Nutrition N/A
Completed NCT05048953 - The Use of Musculoskeletal Ultrasound for the Detection of ICU-Acquired Weakness
Terminated NCT04095533 - ICU Associated Weakness and Bedside Ultrasound Assessment
Terminated NCT04160039 - Early Cycle Ergometry for Critically-Ill Liver Failure Patients in a Transplant Intensive Care Unit N/A
Active, not recruiting NCT04944537 - Current Situation and Analysis of ICU Management for Severe Trauma Patients in China
Recruiting NCT05865314 - Optimised Nutritional Therapy and Early Physiotherapy in Long Term ICU Patients (NutriPhyT Trial) N/A
Completed NCT04810273 - Effect of Progressive Early Mobilization in Patients With TBI N/A
Completed NCT04396197 - Physical Activity Levels in COVID-19 Patients Admitted to Intensive Care
Recruiting NCT04932330 - Risk Factors of ICU-acquired Weakness
Completed NCT05008562 - How COVID-19 Effects to Muscle Mass Change ın ICU?
Recruiting NCT05919940 - Improved Muscle Metabolism by Combination of Muscle Activation and Protein Substitution ( IMEMPRO ) N/A
Recruiting NCT04565002 - Transcutaneous Electrical Diaphragmatic Stimulation in Critically Ill Elderly Patients N/A
Recruiting NCT05396066 - Respiratory and Quadriceps Muscle Fatigability After an ICU Acquired Weakness
Recruiting NCT04998643 - Muscle Catabolism and Outcomes in Children Following Cardiac Surgery
Not yet recruiting NCT06184945 - Behavioral Economic & Staffing Strategies in the ICU N/A
Completed NCT03550222 - Muscle Evaluation Using Ultrasound in the Critically Ill